166 related articles for article (PubMed ID: 22267156)
1. Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction.
Piao SG; Bae SK; Lim SW; Song JH; Chung BH; Choi BS; Yang CW
Transplantation; 2012 Feb; 93(4):383-9. PubMed ID: 22267156
[TBL] [Abstract][Full Text] [Related]
2. Combined treatment of tacrolimus and everolimus increases oxidative stress by pharmacological interactions.
Piao SG; Lim SW; Doh KC; Jin L; Heo SB; Zheng YF; Bae SK; Chung BH; Li C; Yang CW
Transplantation; 2014 Jul; 98(1):22-8. PubMed ID: 24825522
[TBL] [Abstract][Full Text] [Related]
3. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
Lloberas N; Torras J; Alperovich G; Cruzado JM; Giménez-Bonafé P; Herrero-Fresneda I; Franquesa Ml; Rama I; Grinyó JM
Nephrol Dial Transplant; 2008 Oct; 23(10):3111-9. PubMed ID: 18469305
[TBL] [Abstract][Full Text] [Related]
4. Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression of KLOTHO, an antiaging gene.
Han DH; Piao SG; Song JH; Ghee JY; Hwang HS; Choi BS; Kim J; Yang CW
Transplantation; 2010 Jul; 90(2):135-41. PubMed ID: 20562737
[TBL] [Abstract][Full Text] [Related]
5. Influence of sirolimus on cyclosporine-induced pancreas islet dysfunction in rats.
Song HK; Han DH; Song JH; Ghee JY; Piao SG; Kim SH; Yoon HE; Li C; Kim J; Yang CW
Am J Transplant; 2009 Sep; 9(9):2024-33. PubMed ID: 19624561
[TBL] [Abstract][Full Text] [Related]
6. Correlation between cyclosporine-induced nephrotoxicity in reduced nephron mass and expression of kidney injury molecule-1 and aquaporin-2 gene.
Hong ME; Hong JC; Stepkowski S; Kahan BD
Transplant Proc; 2005 Dec; 37(10):4254-8. PubMed ID: 16387092
[TBL] [Abstract][Full Text] [Related]
7. Treatment of chronic allograft nephropathy at late stages using everolimus or FTY720 in combination with cyclosporine.
Roos M; Liu S; Strobl M; Schmaderer C; Baumann M; Heemann U; Lutz J
Transplant Proc; 2008 Dec; 40(10):3731-6. PubMed ID: 19100477
[TBL] [Abstract][Full Text] [Related]
8. The effect of low-dose Continuous Erythropoietin receptor activator in an experimental model of acute Cyclosporine A induced renal injury.
Meerwein C; Korom S; Arni S; Inci I; Weder W; Jungraithmayr W
Eur J Pharmacol; 2011 Dec; 671(1-3):113-9. PubMed ID: 21968143
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus and everolimus intestinal absorption and interaction with calcineurin inhibitors: a differential effect between cyclosporine and tacrolimus.
Lamoureux F; Picard N; Boussera B; Sauvage FL; Marquet P
Fundam Clin Pharmacol; 2012 Aug; 26(4):463-72. PubMed ID: 21631587
[TBL] [Abstract][Full Text] [Related]
10. TGF-β1 mediates sirolimus and cyclosporine A-induced alteration of barrier function in renal epithelial cells via a noncanonical ERK1/2 signaling pathway.
Martin-Martin N; Slattery C; McMorrow T; Ryan MP
Am J Physiol Renal Physiol; 2011 Dec; 301(6):F1281-92. PubMed ID: 21880834
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity.
Shihab FS; Bennett WM; Yi H; Choi SO; Andoh TF
Kidney Int; 2004 Apr; 65(4):1262-71. PubMed ID: 15086465
[TBL] [Abstract][Full Text] [Related]
12. Comparison of early and late conversion of sirolimus in experimental model of chronic cyclosporine nephropathy.
Kim JY; Ghee JY; Lim SW; Piao SG; Chung BH; Yoon HE; Hwang HS; Choi BS; Kim J; Yang CW
J Korean Med Sci; 2012 Feb; 27(2):160-9. PubMed ID: 22323863
[TBL] [Abstract][Full Text] [Related]
13. Serum and renal tissue markers of nephropathy in rats under immunosuppressive therapy: cyclosporine versus sirolimus.
Sereno J; Parada B; Rodrigues-Santos P; Lopes PC; Carvalho E; Vala H; Teixeira-Lemos E; Alves R; Figueiredo A; Mota A; Teixeira F; Reis F
Transplant Proc; 2013 Apr; 45(3):1149-56. PubMed ID: 23622648
[TBL] [Abstract][Full Text] [Related]
14. Effect of low dose cyclosporine and sirolimus on hepatic drug metabolism in the rat1.
Bai S; Brunner LJ; Stepkowski SM; Napoli KL; Kahan BD
Transplantation; 2001 Jun; 71(11):1585-92. PubMed ID: 11435969
[TBL] [Abstract][Full Text] [Related]
15. Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.
Nielsen FT; Ottosen P; Starklint H; Dieperink H
Nephrol Dial Transplant; 2003 Mar; 18(3):491-6. PubMed ID: 12584269
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppressant use without bone loss--implications for bone loss after transplantation.
Goodman GR; Dissanayake IR; Sodam BR; Gorodetsky E; Lu J; Ma YF; Jee WS; Epstein S
J Bone Miner Res; 2001 Jan; 16(1):72-8. PubMed ID: 11149492
[TBL] [Abstract][Full Text] [Related]
17. Human allograft arterial injury is ameliorated by sirolimus and cyclosporine and correlates with suppression of interferon-gamma.
Yi T; Cuchara L; Wang Y; Koh KP; Ranjbaran H; Tellides G; Pober JS; Lorber MI
Transplantation; 2006 Feb; 81(4):559-66. PubMed ID: 16495804
[TBL] [Abstract][Full Text] [Related]
18. Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients.
Felipe CR; Park SI; Pinheiro-Machado PG; Garcia R; Casarini DE; Moreira S; Tedesco-Silva H; Medina-Pestana JO
Fundam Clin Pharmacol; 2009 Oct; 23(5):625-31. PubMed ID: 19656203
[TBL] [Abstract][Full Text] [Related]
19. Role of endothelin-1 and nitric oxide bioavailability in transplant-related vascular injury: comparative effects of rapamycin and cyclosporine.
Ramzy D; Rao V; Tumiati LC; Xu N; Miriuka S; Delgado D; Ross HJ
Circulation; 2006 Jul; 114(1 Suppl):I214-9. PubMed ID: 16820575
[TBL] [Abstract][Full Text] [Related]
20. Preclinical results of sirolimus treatment in transplant models.
Stepkowski SM
Transplant Proc; 2003 May; 35(3 Suppl):219S-226S. PubMed ID: 12742499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
